Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2 in Pretreated Patients With Stage IV Melanoma

NCT01480323 is registered in ClinicalTrials.gov with University Hospital Tuebingen as lead sponsor.

NCT NCT01480323
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01480323 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2 in Pretreated Patients With Stage IV Melanoma
Lead sponsor
University Hospital Tuebingen
Phase
Phase 2
Overall status
Completed
Start date
February 29, 2012
Completion date
June 30, 2015
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma